TFOM,
I, like you probably, was sold on the technology and the unmet medical need in the treatment of SCI.
The logistics of getting the technology into human trials, I believe as a little more than Frank Reynolds was capable of.
To raise money to fund the human trial the pps was dropped from $2.00 to $1.15, not what attracts new or current shareholder to buy and hold. Now we sit at a pps of $.60. I have bought some shares on the way down, but recent management statements: the pps will remain under pressure until the human trial begins and we starting getting data, have not helped the pps.
Do I think this is a great opportunity to get in on this speculative company? I do, but even though I see a decent amount of volume, it hasn't seem to support the pps to this point.
New management has tried to design a trial to get the scaffolding used in a human trial, but I feel the design may limit the number and type of patients that can be enrolled in the trial.
We have waited almost 4 months for the first patient to be enrolled and I will probably continue to try and be patient.
If the technology is tested and provides benefit to patients with SCI, there may yet be a win in this for both the patients and the investors.
Good luck to all, and I hope our patience pays off,
AI
